Take the perspectives of key opinion leaders on some of the most debated topics in oncology which are changing clinical practice.

William Travis

Assessing pathological response after neoadjuvant treatment for NSCLC

Much progress has been made in the standardisation of pathological response but optimising viable tumour cutoffs for predicting long-term outcome after different treatment modalities and by histological type remain key areas for investigation 

By William Travis
Suresh Ramalingam

How long should we give immunotherapy for?

The length of immunotherapy course for metastatic lung cancer was arbitrarily set at 2 years in clinical trials, but definitive studies investigating the optimum duration against the risk-benefit profile are lacking

By Suresh Ramalingam

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.